Thoracic aortic dissection occurs when the intima of the aorta becomes compromised and ... The DeBakey classification: Type I: Dissection originating in the ascending aorta extending a variable ...

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE clinical trial (the "IDE") was presented in a ...

The DeBakey system classifies into more specific loci: type 1 initiates in the ascending aorta at least until the aortic arch, ... (AMI). 8% of AMI diagnoses are Type A aortic dissection.

Additionally, late-breaking data from the AMDS PERSEVERE trial (NCT05174767) determined that patients with acute DeBakey Type I aortic dissection can be treated safely and effectively using the ...

Enter details about all patients having aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissection into the NICOR Adult Cardiac Surgery Audit. Contact ...

The trial consists of 93 participants in the U.S., who have experienced an acute DeBakey Type I aortic dissection. Each participant will be followed for up to 5 years.

On Monday, Oppenheimer reiterated its positive stance on Artivion Inc. (NYSE:AORT), maintaining an Outperform rating and a $32.00 price target. The endorsement comes on the heels of Artivion's ...

The second major data driver is the PERSEVERE study of Artivion's AMDS hybrid prosthesis for acute DeBakey Type 1 aortic dissection, a market worth potentially $500M or more and where there are ...

Endovascular Treatment of Descending Thoracic Aortic Dissection ... prospective study performed in 140 patients with uncomplicated Stanford type B aortic ... Michael E. DeBakey ...

Dr. Fukuhara commented, "Patient outcomes following AMDS treatment of acute DeBakey Type I aortic dissection with malperfusion remain impressive through one year after operation.

ATLANTA, Dec. 9, 2024 /PRNewswire/ --Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug ...

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE clinical trial (the "IDE") was presented in a ...